Self-described female-founded oncology company Phoenix Molecular Designs has started dosing in the Phase II arm of a trial examining its metastatic breast cancer candidate, PMD-026. The Phase I/Ib ...

Turnover has risen up close to the £2bn mark at the acquisitive RSK Group, although the environmental services business also reported widened losses of more than £130m. Founded in 1989 by its chief ...

The Phase I/Ib/II trial (NCT04115306) is moving on to its third part which will see the oral ribosomal s6 kinase (RSK) inhibitor examined in combination with fulvestrant in HER 2, +HR and RSK2 ...